Tirzepatide vs Tesamorelin
Side-by-side comparison of Tirzepatide, Tesamorelin — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss | Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | Dual GIP/GLP-1 Receptor Agonist | GHRH Analogue |
| Amino acids | 39 | 44 |
| Molecular weight | 4,813.5 Da | 5,135.8 Da |
| Half-life | ~5 days | ~30 min |
| Route(s) | Subcutaneous injection | Subcutaneous |
| Mechanism & Research | ||
| Primary mechanism | Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… | Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its … |
| Research status | FDA Approved | FDA Approved |
| Evidence summary | Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… | Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s… |
| Protocol & Dosing | ||
| Typical dose | 2.5mg → 15mg weekly | 2 mg/day |
| Frequency | Once weekly | Once daily |
| Duration | Ongoing (chronic) | 26–52 weeks (clinical) |
| Timing | Same day each week, any time of day | Before breakfast or bedtime |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Semaglutide, AOD-9604, Tesamorelin | CJC-1295, Sermorelin, AOD-9604 |
| Full profile | Read full Tirzepatide profile → | Read full Tesamorelin profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.